Cagrilintide

Scientific Overview

Cagrilintide is a lipidated analog of amylin, a pancreatic peptide involved in satiety signaling. Published work describes it as a long-acting amylin analog for receptor and metabolic research.

Mechanism focus

Amylin signals through calcitonin-receptor complexes with receptor-activity-modifying proteins. Research on cagrilintide focuses on that pharmacology and on how a prolonged amylin-receptor agonist behaves in experimental models.

Research Use Cases

• Amylin-receptor pharmacology
• Satiety and energy-balance signaling models
• Comparison with other metabolic peptide analogs
• Analytical identity of lipidated amylin analogs

Use-Case Study Notations

• Case-study notation: development papers describe cagrilintide as a long-acting amylin analogue.
• Case-study notation: later reviews place it in the amylin-receptor literature alongside other metabolic peptide research.
• This page summarizes research context. It does not state clinical outcome claims.

Selected Studies

1. 01 Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialPubMed 34798060
2. 02 Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight managementPubMed 33894838
3. 03 Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesPubMed 40544432
4. 04 Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2)PubMed 42251859
5. 05 Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on metforminPubMed 42251860

Related compounds

Semaglutide · AOD-9604